Simvastatin significantly reduced HMGB1 and IL-1β level, which suggested that simvastatin ameliorated vascular pathology in T2DM rats through NLRP3 inflammasome dependent HMGB1 release. The gene discussed is NLRP3; the disease is type 2 diabetes mellitus.